Personalis, Inc. $PSNL Shares Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC increased its stake in Personalis, Inc. (NASDAQ:PSNL) by 150.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,000 shares of the company’s stock after buying an additional 45,000 shares during the period. Janney Montgomery Scott LLC owned about 0.07% of Personalis worth $478,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd grew its holdings in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Personalis in the 2nd quarter worth about $30,000. International Assets Investment Management LLC acquired a new stake in shares of Personalis in the 4th quarter valued at about $31,000. BNP Paribas Financial Markets raised its stake in shares of Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth bought a new position in shares of Personalis during the first quarter worth about $47,000. 61.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PSNL has been the subject of a number of research reports. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. BTIG Research reduced their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday. Morgan Stanley boosted their price target on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Insider Activity

In other news, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,103,215.90. This trade represents a 29.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at $2,620,618.94. The trade was a 20.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 435,032 shares of company stock worth $5,599,929. 4.20% of the stock is owned by corporate insiders.

Personalis Trading Up 5.1%

NASDAQ PSNL opened at $15.79 on Thursday. The company has a 50-day moving average price of $10.56 and a two-hundred day moving average price of $8.80. Personalis, Inc. has a 52 week low of $3.84 and a 52 week high of $16.15. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -15.48 and a beta of 2.24.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. As a group, equities research analysts expect that Personalis, Inc. will post -1.07 earnings per share for the current fiscal year.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.